利用基于pQTL的门德尔随机化来确定初级胆管胆炎和初级硬化胆炎的新治疗前景
Lei Dai1, Yunyan Ye2, Joseph Mugaany1,3
1Department of Hepato-Pancreato-Biliary Surgery, Ningbo Medical Centre Lihuili Hospital, The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315040, China.
Aging
|May 29, 2024
概括
这项研究确定了自身免疫性胆道疾病的新型可用药物点. LEFTY2和HSPB1对原发性胆道胆炎 (PBC) 是有前途的,而FCGR3B则是原发性硬化胆炎 (PSC) 的强有力的候选者.
科学领域:
- 遗传学和精准医学 遗传学和精准医学
- 肝病学和自身免疫性疾病
背景情况:
- 原发性胆道胆炎 (PBC) 和原发性硬化胆炎 (PSC) 是慢性自身免疫性肝脏疾病,导致胆道逐渐受损.
- 目前对PBC和PSC的治疗选择有限,需要确定新的治疗点.
研究的目的:
- 通过使用孟德尔随机化 (MR) 方法来确定PBC和PSC的可用药物标.
- 为了验证潜在的治疗候选者,并预测这些具有挑战性的自身免疫性肝病的药物.
主要方法:
- 使用Cis-pQTL数据 (deCODE) 和PBC和PSC (FINNGEN) 的GWAS数据进行了门德尔随机化分析.
- 进行了局部化分析,以确认共享的遗传关联.
- 通过使用GSE119600数据集验证基因表达,免疫组织化学和通过DRUGBANK数据库预测药物.
主要成果:
- 通过MR分析,通过MR分析确定了PBC和PSC的八个潜在的可用药物标.
- LEFTY2显示强有力的证据作为PBC的治疗标,HSPB1显示中等的证据.
- FCGR3B已经成为PSC的强有力的治疗候选者. 这些基因的高调表达在患者样本中得到证实.
结论:
- 这项研究成功地确定了LEFTY2和HSPB1作为PBC的新药可用标,以及PSC的FCGR3B.
- 这些发现为管理PBC和PSC提供了有希望的新治疗途径,解决未满足的临床需求.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
120
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
120